- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVS
Recent news which mentions NVS
Novartis Injects $300M In Early-Stage Biologics Research Tech
September 12, 2022
Tickers
NVS
From Benzinga
Novartis' Kisqali Adds One More Year Of Survival Benefit In Breast Cancer Setting
September 09, 2022
Tickers
NVS
From Benzinga
No Early Relief for JW Therapeutics from Cancer Wonder Drug
September 07, 2022
From Benzinga
From Benzinga
Novartis Appoints Merck Executive As Research Head
September 01, 2022
From Benzinga
From Benzinga
U.S.-China relations just got a whole lot better, boosting the prospects of these three stocks
August 28, 2022
From MarketWatch
With Sandoz Spinoff, Novartis Slams Brakes On Huntington's Trial
August 25, 2022
Tickers
NVS
From Benzinga
From Benzinga
Fed heroics or no, the S&P 500 level is destined for a retest of lows. These are the levels to watch, says this strategist
August 25, 2022
From MarketWatch
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
August 18, 2022
From Benzinga
A Look Into Healthcare Sector Value Stocks
August 15, 2022
From Benzinga
From Benzinga
From Benzinga
Deciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal Cancer
August 11, 2022
From Benzinga
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
August 08, 2022
From Benzinga
From Benzinga
Tickers
NVS
From Motley Fool
Alnylam's Strategy Is Getting Bigger. Time to Buy?
July 30, 2022
From Motley Fool
From Benzinga
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
July 27, 2022
From Benzinga
7 Cathie Wood Stocks Trading at a Discount Right Now
July 26, 2022
From InvestorPlace
From Benzinga
From Benzinga
From Benzinga
What This FDA Delay Means for Novartis
July 21, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.